SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TRUMP is a politics-themed digital coin built on the Solana blockchain that uses the brand of Donald Trump to foster a community-driven ecosystem. As a community-focused asset, it is designed to bridge political support with web ownership, operating within the PolitiFi sector to blend political movements with decentralized finance tools. The project's main value proposition lies in its official ties to Donald Trump’s media and business brands, which allows it to provide unique physical utility such as invitations to gala dinners and meetings at Mar-a-Lago.  The token serves as the primary currency for the officially licensed Trump Billionaires Club mobile and web game, where it is used for in-game purchases and unlocking features. By leveraging the Solana blockchain, the project ensures that these in-game actions and token transfers remain fast and cost-effective. The ecosystem remains stable through a programmatic release schedule that introduces new tokens slowly to prevent supply shocks, alongside the use of specialized market makers to maintain consistent liquidity for traders.  Holders can also participate in liquidity sharing by providing their tokens to automated systems to facilitate trading for others, often earning rewards or prizes in return. Beyond digital utility, holding a specific amount of the token is a requirement for attending exclusive real-world events, including VIP parties at Mar-a-Lago. The project is managed by the Trump Meme Team and is linked with Trump Media, with an investor base that includes a wide range of retail buyers and large holders who utilize secure custody services for their assets.

Trump For President

$TRUMP.X is facing intense community backlash following financial disclosures revealing the Trump family earned over $1 billion from crypto ventures while most retail holders have seen their investments collapse. Investors are actively debating whether the token is a failed pump-and-dump scheme or a potential value opportunity, with significant tension between those calling it a grift and those framing the market volatility as a typical speculative casino.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

Rigel Pharmaceuticals is trending as investors focus on its strong earnings momentum and the upcoming launch of its new oncology drug, Veppanu. While the community is actively debating the company's long-term valuation and potential for a strategic buyout, discussions remain centered on the company's profitability and its expanding commercial oncology pipeline.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

The AMP token is trending amidst intense community debate over its long-term viability and recent price decline, with sentiment split between disillusioned "bagholders" calling it a failed project and resilient believers clinging to hopes of institutional adoption and regulatory clarity. While the community actively questions leadership transparency and the lack of tangible network usage, the recurring presence of the symbol in top trending charts continues to drive speculation about potential utility-driven rebounds.

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Abeona Therapeutics Inc

Abeona Therapeutics is trending as investors focus on the commercial ramp-up of ZEVASKYN, with community discussions centering on the rollout of qualified treatment centers and the potential for near-term profitability. Sentiment is driven by anticipation of upcoming earnings and clinical milestones, while active traders closely monitor high short interest and institutional accumulation patterns.

Re is an internet-native marketplace for insurance capital. It connects eligible capital providers with fully collateralized reinsurance activity conducted through licensed insurance entities. Blockchain infrastructure makes collateral, reserves, and selected operating data verifiable onchain. RE is the governance token of the Re Protocol. It governs protocol upgrades, technical permissions, committee formation, reporting standards, incentive policy, and governance procedures. Underwriting, claims, pricing, reserve decisions, and regulated operations remain with qualified professionals and licensed entities.

RE is trending as investors react to its recent listing on major trading platforms and speculative interest surrounding its utility in the decentralized reinsurance and energy sectors. Community members are actively debating the token's growth potential while closely monitoring price action and institutional-backed developments.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines is trending following positive Phase 3 clinical trial results for its drug daraxonrasib in treating metastatic pancreatic cancer, which demonstrated a significant survival advantage over standard chemotherapy. Community discussion is heavily focused on the stock's potential as a major buyout candidate and the broader shift of investor capital toward innovative oncology biotech.

Stellantis NV engages in the designing, engineering, manufacturing, distributing, and selling of vehicles and components. It offers its products under the Abarth, Alfa Romeo, Chrysler, Citroën, Dodge, DS Automobiles, Fiat, Jeep, Lancia, Maserati, Opel, Peugeot, Ram Trucks, Vauxhall, Free2move, and Leasys brands. The company was founded on April 1, 2014 and is headquartered in Hoofddorp, the Netherlands.

Stellantis N.V

Stellantis stock is facing heavy selling pressure following a massive $26 billion charge tied to an aggressive restructuring plan, which includes suspending the dividend and reevaluating its electrification strategy. Community sentiment is deeply divided, with many traders viewing the stock as a distressed deep-value play while others express frustration over management's past product decisions and the lack of immediate turnaround clarity.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is currently a focal point for investors due to positive technical momentum and community excitement surrounding its lead drug candidate, soquelitinib. The stock is seeing heavy short interest, fueling intense discussion among market participants about potential short squeezes and the possibility of a future buyout or major partnership as the company advances its pipeline of novel immunology and oncology therapies.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

Shiba Inu is facing intense polarization as community members debate whether the current price represents a buying opportunity or a terminal decline for the token. Discussions are dominated by frustration over stagnant performance compared to newer meme coins, with some investors aggressively promoting alternative projects while others remain committed to long-term holding.

Chip

Chip is trending as investors debate its role as a GPU-backed lending protocol financing AI infrastructure versus concerns regarding its volatile tokenomics and historical price slides. While some community members highlight the protocol's real-world utility and recent volume, others remain skeptical, warning of potential insider sell-offs and aggressive short-selling activity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Teva Pharmaceutical Industries Limited (TEVA) Stock Undervalued After Recent Pullback and Vitiligo Program Update?

Is Teva Pharmaceutical Industries Limited (TEVA) Stock Undervalued After Recent Pullback and Vitiligo Program Update...

Is Teva Pharmaceutical Industries Limited (TEVA) Strengthening Its Neurology Portfolio With New Austedo Results?

Is Teva Pharmaceutical Industries Limited (TEVA) Strengthening Its Neurology Portfolio With New Austedo Results...

Merck's Anti-TL1A Antibody Meets Goal in Ulcerative Colitis Study

MRK's tulisokibart meets goals in a late-stage ulcerative colitis study, strengthening a key pipeline asset as the company looks beyond Keytruda.

Teva's Shift Beyond Generics Puts Focus on Branded Drug Growth

TEVA is expanding its branded drugs portfolio as Austedo, Ajovy and Uzedy drive higher-margin growth and reshape its business mix.

Teva Seeks FDA Nod for Ecopipam in Pediatric Tourette Syndrome

TEVA files an NDA with the FDA seeking approval of ecopipam for the treatment of pediatric Tourette syndrome.

J&J Stock Down 3% in 3 Months: Is the Dip a Buying Opportunity?

J&J's shares fall 3% in three months despite solid results and pipeline progress, raising questions about whether the pullback is a buying opportunity.

Is Amneal a Buy Before Rytary Generic Erosion?

AMRX faces Rytary generic pressure in 2026, but growth in generics, injectables, biosimilars, and higher profitability targets could support its outlook.

ALVO Stock Gains 19% on FDA Resubmission of Biosimilar BLAs 

Alvotech shares surge after the company resubmits FDA applications for its biosimilar candidates, AVT05 and AVT06, with reviews expected within six months.

3 Generic Drug Stocks to Watch as New Growth Drivers Emerge

Sandoz, Teva and Viatris target biosimilars, complex generics and specialty drugs as new growth drivers reshape the Medical - Generic Drugs industry.

Can JNJ Sustain Growth Amid Patent, Legal and China Risks?

J&J faces Stelara erosion, China MedTech pressure and talc litigation, but targets $100B revenues and faster growth in 2026.

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Teva- Pharmaceutical Industries Ltd. - ADR

Teva Pharmaceuticals Seeks FDA Greenlight For New Schizophrenia Treatment 

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

TEVATeva- Pharmaceutical Industries Ltd. - ADR

Fundamentals

Latest TEVA News